An international team of biologists urge careful use of technology in research and flag potential biosafety risks.
The use of gene-editing technology to create virus-resistant cassava plants could have serious negative ramifications, according to new research by plant biologists at the University of Alberta, the University of Liege in Belgium, and the Swiss Federal Institute of Technology. Their results show that attempts to genetically engineer the plants to fight off viruses, in fact resulted in the propagation of mutated viruses in controlled laboratory conditions.
“We concluded that because this technology both creates a selection pressure on the viruses to evolve more quickly, and also provides the viruses a means to evolve, it resulted in a virus mutant that is resistant to our interventions,” explained Devang Mehta, postdoctoral fellow in the Department of Biological Sciences. CRISPR-Cas9 is found in nature, where bacteria use it to defend against viruses, however the researchers found that the technology results in very different outcomes in plants—and researchers are stressing the importance of screening against these sorts of unintended results in the future.
The cassava plant, the object of the study, is a starchy root vegetable that is consumed for food throughout the tropics. Cassava is a primary staple crop grown in South America, Africa, and Asia, from which 1 billion people get most of their calories each day. Each year, cassava crops are plagued by cassava mosaic disease, which causes 20 per cent crop loss. It is the mosaic disease that Mehta and his colleagues endeavoured to engineer against.
Unsuccessful results
The researchers used a new gene-editing technology called CRISPR-Cas9 to attempt to design cassava plants that could cut the DNA of the mosaic virus and make the plants resistant to its damaging effects. Unfortunately, their results were not successful. To understand what happened, the team sequenced hundreds of viral genomes found in each plant.
“We discovered that the pressure that CRISPR-Cas9 applied to the virus probably encouraged it to evolve in a way that increased resistance to intervention,” said Mehta. Mehta hastens to add that CRISPR-Cas9 has many other applications in food and agriculture that do not pose the same risks.
The research team is keen to share their results with other scientists who are using CRISPR-Cas9 technology to engineer virus-resistant plants, and encourage these groups to test their plants to detect similar viral mutations.
“We need to do more research on these types of applications of CRISPR-Cas9 technology before we proceed with field testing” said Mehta. Mehta, a postdoctoral fellow with Professor Glen Uhrig, began this research during his PhD studies at the Swiss Federal Institute of Technology (ETH) in Zurich.
Learn more: Gene-editing technology may produce resistant virus in cassava plant
The Latest on: Gene editing caution
[google_news title=”” keyword=”gene editing caution” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Gene editing caution
- Regeneron inks $100M deal to develop gene-editing therapieson April 26, 2024 at 2:33 am
Tarrytown-based Regeneron Pharmaceuticals has struck a $100 million deal with Mammoth Biosciences, a California-based biotechnology company, to develop and commercialize gene editing therapies for ...
- Regeneron, Mammoth Launch In Vivo CRISPR Gene Editing Collaborationon April 25, 2024 at 8:00 am
Regeneron Pharmaceuticals will use Mammoth Biosciences’ CRISPR-based ultracompact gene editing platform to develop in vivo therapies for tissues and cell types beyond the liver.
- Regeneron to collaborate on gene editing therapies with Doudna-founded Mammothon April 25, 2024 at 7:10 am
Regeneron Pharmaceuticals and Mammoth Biosciences will collaborate to research, develop and commercialize gene editing therapies for multiple diseases, the companies said on Thursday.
- Regeneron signs Mammoth gene editing deal worth $100M upfronton April 25, 2024 at 1:49 am
Regeneron is signing another major deal in gene editing—and, this time, it’s Mammoth. Mammoth Biosciences, that is. The companies will collaborate on in vivo CRISPR-based gene editing therapies in a ...
- AI-designed gene editing tools successfully modify human DNAon April 24, 2024 at 5:51 am
Medically, AI is helping us with everything from identifying abnormal heart rhythms before they happen to spotting skin cancer. But do we really need it to get involved with our genome? Protein-design ...
- GU Medical Center Distinguished Scientist Seminar Series Illuminates Uses of Gene Editing in Cancer Researchon April 23, 2024 at 5:00 pm
A researcher highlighted gene editing and its therapeutic applications in a talk April 18. Raj Chari, director of the Genome Modification Core Laboratory at the Frederick National Laboratory for ...
- Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCson April 22, 2024 at 3:30 pm
This novel editing approach might unlock new strategies for the treatment of metabolic and neurological diseasesNon-viral circular ssDNA delivery ...
- Generative A.I. Arrives in the Gene Editing World of CRISPRon April 22, 2024 at 1:48 pm
Much as ChatGPT generates poetry, a new A.I. system devises blueprints for microscopic mechanisms that can edit your DNA.
- The First Successful Xenotransplantation of a Gene-Edited Pig Kidney Raises Hopes and Questionson March 30, 2024 at 3:53 am
CRISPR/Cas9, dubbed as “genetic scissors,” has revolutionized gene editing over the last decade ... they also remind us of the need for caution, with much work remaining to ensure long ...
- CRISPR Gene-Editing Emerges as a Potential Game-Changer in the Battle Against HIVon March 28, 2024 at 9:22 pm
Despite these promising developments, experts urge caution and patience ... GMT – Hopes of HIV cure after breakthrough using gene-editing ‘scissors’, Sky News, Wed, 20 Mar 2024 04: ...
via Bing News